Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report

Abstract: Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC. A pilot study demonstrated a high rate of pathologic complete response using cemiplimab in the neoadjuvant setting. Case Presentation: Here, we report the case of an 84-year-old man with two locally advanced unresectable cSCCs (a nasolabial lesion and a retroauricular lesion) treated with cemiplimab, for whom closer follow-up revealed a complete response of the retroauricular lesion and a partial response of the nasolabial lesion after 4 cycles. Patient will be submitted to nasolabial lesion resection. Conclusion: This illustrates the efficacy of the use of cemiplimab as preoperative therapy in advanced unresectable cSCC, facilitating a definitive surgical treatment.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report ; volume:17 ; number:1 ; year:2024 ; pages:1109-1114 ; extent:6 ; Case reports in oncology ; 17, Heft 1 (2024), 1109-1114 (gesamt 6)

Contributors, Places and Time

• Creator: Cabral, Sara Cerqueira ; Gouveia, Emanuel ; Nunes, Hugo ; Pereira, Patricia M.

Further information

• DOI: 10.1159/000540842
• URN: urn:nbn:de:101:1-2411272332552.961423479637
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:32 AM CEST